The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.


Serval ID
Article: article from journal or magazin.
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.
Annals of Oncology
Colleoni M., Sun Z., Martinelli G., Basser R.L., Coates A.S., Gelber R.D., Green M.D., Peccatori F., Cinieri S., Aebi S., Viale G., Price K.N., Goldhirsch A.
Working group(s)
International Breast Cancer Study Group
Basser R., Goldhirsch A., Coates AS., Aebi S., Coates AS., Colleoni M., Collins JP., Cortés Funes H., Gelber RD., Goldhirsch A., Green M., Hiltbrunner A., Holmberg SB., Karlsson P., Kössler I., Láng I., Lindtner J., Paganetti F., de Stoppani M., Rudenstam CM., Senn HJ., Stahel R., Thürlimann B., Veronesi A., Hiltbrunner A., Egli G., Rabaglio M., Ruepp B., Maibach R., Gelber RD., Price K., Sun Z., Regan M., Cole B., Gelber S., Giobbie-Hurder A., Aldridge J., Bernhard J., Ribi K., Gerber D., Gusterson B., Viale G., Blacher L., Celano J., Hinkle R., Lippert S., Scott K., Forbes JF., Lindsay D., Preece D., Simes RJ., Collins J., Snyder R., Abdi E., Basser R., Burns WI., Chipman M., Chirgwin J., Ganju V., Green M., McLachlan S., Howell D., Prince M., Schwarer A., Toner G., Underhill C., Craft P., Harris S., Pembrey R., Forbes JF., Stewart J., Ackland S., Bonaventura A., Taylor K., Friedlander M., Brigham B., Lewis C., Goldstein D., Kotasek D., Olver IN., Gill PG., Keefe D., Abraham R., Wyld D., Boyle F., Durrant S., Bell D., Beith J., Boyer M., Coates AS., Sullivan A., Byrne M., van Hazel G., Dewar J., Harvey VJ., Thompson P., Porter D., McCrystal M., Martinelli G., Peccatori F., Veronesi U., Viale G., Luini A., Orecchia R., Cinieri S., Cocorocchio E., Renne G., Mazzarol G., Colleoni M., Agazzi A., Nolé F., Costa A., Zurrida S., Veronesi P., Sacchini V., Galimberti V., de Braud F., Peruzzotti G., Didier F., Goldhirsch A., Ravaioli A., Tassinari D., Oliverio G., Barbanti F., Rinaldi P., Gianni L., Drudi G., Wickham N., Leung T., Yeo W., King W., Kwan W., Suen M., Chak K., Lee L., Fey MF., Aebi S., Dreher E., Schneider H., Buser K., Ludin J., Beck G., Bürgi H., Haenel A., Lüthi JM., Markwalder R., Altermatt HJ., Nandedkar M., Senn HJ., Thürlimann B., Ries G., Töpfer M., Lorenz U., Schiltknecht O., Späti B., Cavalli F., Sessa C., Martinelli G., Ghielmini M., Luscieti P., Bernier J., Pedrinis E., Rusca T., Goldhirsch A., Perey L., Leyvraz S., Anani P., Genton C., Gomez F., De Grandi P., Reymond P., Mirimanoff R., Gillet M., Delaloye JF., Alberto P., Bonnefoi H., Schäfer P., Krauer F., Forni M., Aapro M., Egeli R., Megevand R., Jacot-des-Combes E., Schindler A., Borisch B., Diebold S., Sauter Ch., Metzger U., Engeler V., Haller U., Caduff R., Lindtner J., Erzen D., Majdic E., Stabuc B., Plesnicar A., Golouh R., Lamovec J., Jancar J., Vrhoved I., Kramberger M.
1569-8041 (Electronic)
Publication state
Issued date
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't Publication Status: ppublish
BACKGROUND: The role of adjuvant dose-intensive chemotherapy and its efficacy according to baseline features has not yet been established.
PATIENTS AND METHODS: Three hundred and forty-four patients were randomized to receive seven courses of standard-dose chemotherapy (SD-CT) or three cycles of dose-intensive epirubicin and cyclophosphamide (epirubicin 200 mg/m(2) plus cyclophosphamide 4 mg/m(2) with filgrastim and progenitor cell support). All patients were assigned tamoxifen at the completion of chemotherapy. The primary end point was disease-free survival (DFS). This paper updates the results and explores patterns of recurrence according to predicting baseline features.
RESULTS: At 8.3-years median follow-up, patients assigned DI-EC had a significantly better DFS compared with those assigned SD-CT [8-year DFS percent 47% and 37%, respectively, hazard ratio (HR) 0.76; 95% confidence interval 0.58-1.00; P = 0.05]. Only patients with estrogen receptor (ER)-positive disease benefited from the DI-EC (HR 0.61; 95% confidence interval 0.39, 0.95; P = 0.03).
CONCLUSIONS: After prolonged follow-up, DI-EC significantly improved DFS, but the effect was observed only in patients with ER-positive disease, leading to the hypothesis that efficacy of DI-EC may relate to its endocrine effects. Further studies designed to confirm the importance of endocrine responsiveness in patients treated with dose-intensive chemotherapy are encouraged.
Adult, Aged, Amenorrhea, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Breast Neoplasms/drug therapy, Breast Neoplasms/metabolism, Cyclophosphamide/administration & dosage, Disease-Free Survival, Dose-Response Relationship, Drug, Epirubicin/administration & dosage, Female, Granulocyte Colony-Stimulating Factor/administration & dosage, Humans, Middle Aged, Neoplasms, Hormone-Dependent/drug therapy, Neoplasms, Hormone-Dependent/metabolism, Receptors, Estrogen/biosynthesis, Recombinant Proteins, Stem Cell Transplantation, Survival Rate, Tamoxifen/administration & dosage, Treatment Outcome
Web of science
Open Access
Create date
03/02/2010 11:58
Last modification date
20/08/2019 16:47
Usage data